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Abstract
BRAFV600E mutations are involved in the development of melanoma, colon cancer, and papillary thyroid carcinoma.
These mutations are also found in primary brain tumors at low to moderate frequencies. In this study, we investi-
gated a series of brain tumors to determine the prevalence and associated clinicopathologic features of BRAFV600E
mutations. By direct sequencing, we analyzed 223 brain tumors, including 51 gangliogliomas (GGs), 45 pilocytic
astrocytomas (PAs), 12 pleomorphic xanthoastrocytomas (PXAs), 35 glioblastomas (GBs), 28 anaplastic astro-
cytomas (AAs), 44 oligodendroglial tumors (ODGs), 3 anaplastic oligoastrocytomas, and 5 diffuse astrocytomas.
Thirty-six cases (16.1%) exhibited the BRAFV600E mutation, including 66.7% of PXAs, 23.5% of GGs, 15.6% of
PAs, and 9.7% of the malignant gliomas; the latter included 14.3% of AAs, 8.6% of GBs, and 4.5% of ODGs. Copy
number aberration at the 7q34 (BRAF) locus was found in 73.1% of PAs and 50% of PXAs. 9p Homozygous deletion
was found in 66.7% of PXAs, but it was not correlated with the BRAFV600E mutation. Patients’ age, sex, histologic
grade, and progression-free survival were also not correlated with the BRAFV600E mutation. The BRAFV600E mutation
in brain tumors did not have prognostic value but is certainly a diagnostic marker and therapeutic target, not only for
pediatric low-grade gliomas but also for malignant gliomas, even though the rate of mutation was not high. These
results should be verified in a larger study with more cases and a longer follow-up period to overcome the limitation
of small sample size.
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Introduction
As a member of the RAF family of serine/threonine kinases, BRAF is a
key mediator of the RAS-RAF-mitogen-activated ERK kinase (MEK)-
extracellular signal-regulated kinases (ERK)-microtubule-associated
protein (MAP) kinase signaling pathway. BRAF is involved in a wide
variety of cellular functions, including cell proliferation, cell cycle arrest,
terminal differentiation, and apoptosis [1]. The BRAF gene is activated
by mutations, predominantly in malignant melanomas (about 65%),
papillary thyroid carcinomas (53%), and colorectal carcinomas [2–4].
Most BRAF mutations are missense mutations at amino acid posi-
tion 600, resulting in an exchange of valine for glutamate (referred to
as BRAFV600E).
The BRAFV600E mutation has also been reported in some brain
tumors, including astrocytic tumors, oligodendroglial tumors
(ODGs), and ependymal tumors, but at relatively low rates (up to
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5.9%) [5–9]. These findings have discouraged further investigation
of this mutation in brain tumors. However, Schindler et al. [10] found
a significant BRAFV600E mutation rate of 60% to 65% for pleomorphic
xanthoastrocytomas (PXAs), 18% for gangliogliomas (GGs), and 9%
for pilocytic astrocytomas (PAs). Dias-Santagata et al. [11] also found
the BRAFV600E mutation in 60% of World Health Organization
(WHO) grade II PXAs, 17% of PXAs with anaplasia, and one glio-
blastoma (GB) arising in a PXA. These are low-grade glioneuronal
and astrocytic tumors, which commonly occurred in children and
adolescence. However, the BRAFV600E mutation has not been detected
in a series of pediatric brain tumors, including desmoplastic infantile
GGs, medulloblastomas, central nervous system (CNS) primitive
neuroectodermal tumors, atypical teratoid/rhabdoid tumors, central
neurocytomas, and dysembryoplastic neuroepithelial tumors [12–15].
So far, the most common genetic abnormality in PAs is a BRAF dup-
lication caused by BRAF-KIAA1549 fusion. The BRAF-KIAA1549
fusion has been detected in 60% to 80% of PAs, and Hawkins et al.
[16,17] reported that the BRAF-KIAA fusion predicted the best clinical
outcome among pediatric low-grade astrocytomas. The homozygous
deletion (HD) of CDKN2A was initially found in a comparative
genomic hybridization study, which found a deletion of 9p21.3 in
60% of PXAs [18]. Michaloglou et al. [19] suggested that the
BRAFV600E mutation induced the CDKN2A mutation, leading to
senescence in human melanocytic nevi. The HD of CDKN2A has
been found in grade II to IV gliomas but not in grade I gliomas.
The KIAA1549-BRAF fusion and BRAFV600E mutation occurred
mutually exclusively. The KIAA1549-BRAF fusion product has been
commonly detected in WHO grade I PAs, which resulted in BRAF
duplication (gain), but this fusion product was not found in grade II
to IV gliomas [15]. The BRAFV600E mutation was found in 18% of
PAs, which was frequently associated with the HD of CDKN2A,
because 71% of BRAFV600E-mutated tumors showed the HD of
CDKN2A and these tumors were in pediatric malignant gliomas
(grades II to IV) [15]. In addition, HD of CDKN2A is known to be
associated with malignant progression [20]. Dias-Santagata et al. [11]
did not observed the KIAA-BRAF fusion in PXA.
The importance of the BRAFV600E mutation in certain brain tumors
is being emphasized as similar to the IDH1 mutation. The role of the
BRAF mutation has been well established in extracranial tumors, which
commonly implicate this mutation. This mutation is closely related with
an increased rate of papillary thyroid carcinoma recurrence and tumor-
related mortality [21,22]. Additionally, it seems to be a strong negative
prognostic factor for colorectal carcinoma, and increasing evidence sug-
gests that this mutation corresponds with resistance to anti–epidermal
growth factor receptor (EGFR) therapy [22–24]. Most importantly,
the possibility of using the BRAF mutation as a therapeutic target has
been suggested, and preclinical and clinical trials as well as a randomized
phase III study of PLX4032 (RAF inhibitor) were conducted in patients
with metastatic melanomas and PLX4720 for malignant astrocytomas
[22,25–28]. Sustained tumor stasis and regressions are observed with oral
administration of BRAF inhibitor CEP-32496 (30 to 100 mg/kg twice
daily) against BRAFV600E melanoma and colon carcinoma xenografts,
without adverse effects [29]. However, only mutation frequencies have
emerged as significant results in brain tumors, despite repeated attempts
to identify the functional role and mechanism of the BRAFV600E muta-
tion in tumorigenesis. To identify the incidence and clinicopathologic
characteristics of BRAFV600E-carrying brain tumors, this study investi-
gated the mutation rate and diagnostic and prognostic values of the
BRAFV600E mutation in diverse gliomas in a Korean population.
Materials and Methods
Tissue Samples
Representative paraffin blocks from human brain tumors diagnosed
at the Department of Neuropathology, Seoul National University
Hospital were obtained from 2000 to 2011. In total, 223 brain tumors
were investigated, including 51 GGs, 45 PAs, 12 PXAs, 35 GBs, 28
anaplastic astrocytomas (AAs), 27 oligodendrogliomas (Os), 17 ana-
plastic oligodendrogliomas (AOs), 3 anaplastic oligoastrocytomas
(AOAs), and 5 diffuse astrocytomas (DAs).
DNA Extraction
Tumor areas were manually microdissected from 6-μm unstained
histologic sections obtained from formalin-fixed and paraffin-embedded
(FFPE) tissue. DNA was isolated from the target using a DNeasy Blood
and Tissue Kit (Qiagen, Valencia, CA) according to the manufac-
turer’s instructions.
Polymerase Chain Reaction Amplification
One microliter of template DNA was added to 100 μl of poly-
merase chain reaction (PCR) solution (10 μl of 10× MG Taq-HF
buffer, 10 μl of 2 mM MG deoxynucleotide triphosphate (dNTP)
mixture, 5 μl of 10 pmol Primer [X2], 1 μl of MGTaq-HF polymer-
ase, and distilled water). The BRAF-F/BRAF-R primers (Table 1)
were used with the following program: 35 cycles of 94°C for 45 sec-
onds, 55°C for 45 seconds, and 72°C for 45 seconds. The products
were about 200 bp in length.
Purification and Sequencing of the PCR Products
Unincorporated PCR primers and dNTPs were removed from the
PCR products using aMontage PCRClean-up Kit (Millipore, Billerica,
MA). The purified products were sequenced using the same two primers
as described (Table 1). Sequencing was performed using a BigDye
Terminator Cycle Sequencing Kit v.3.1 (Applied Biosystems, Foster
City, CA). The sequencing products were resolved on an Applied
Biosystems model 3730XL Automated DNA Sequencing System at
Macrogen, Inc (Seoul, Korea).
Fluorescence In Situ Hybridization
An analysis of 1p, 19q, 9p21.3 (CDKN2A), 7q34 (BRAF), and
EGFR gene status was conducted by fluorescence in situ hybridi-
zation (FISH) using Vysis probes. Four-micrometer sections were
deparaffinized by xylene, incubated with 0.3% pepsin in 10 mM HCl
at 37°C for 10 minutes, boiled with citrate buffer (pH 6.0) in a micro-
wave, incubated in 1 M NaSCN for 35 minutes at 80°C, immersed
in the pepsin solution, and fixed in 10% neutral buffered formalin.
Labeled locus-specific (LSI) EGFR/CEP7 dual-color probes (Abbott
Molecular), LSI CDKN2A/CEP9 dual-color probes (Abbott
Molecular), LSI 7q34/CEP 7 dual-color probes (Abbott Molecular),
and digoxigenin–LSI 1p36 and 19q13 probes, according to the man-
ufacturer’s protocol, were used for recognizing the EGFR gene,
CDKN2A (9p21.3) gene, BRAF (7q34), 1p, and 19q chromosomal
Table 1. Primers Used for Amplification and Sequencing.
Amplification Sequencing
BRAF-F GCTTGCTCTGATAGGAAAATGAG • •
BRAF-R GTAACTCAGCAGCATCTCAGG • •
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status. We applied the probe mixture to the slides and incubated the
slides in a humidified atmosphere with HYBrite (Abbott Molecular,
Des Plaines, IL) at 73°C for 5 minutes for simultaneous denaturation
of the probe and target DNA. Then, we changed the temperature to
37°C for 19 hours to hybridize the probes and target DNA. The
slides were soaked in 0.4× SSC buffer/0.3% NP-40 for 2 minutes
at room temperature, followed by 2× SSC/0.1% NP-40 for 5 min-
utes at 73°C. The processing and analysis of the FISH studies were
conducted as described previously [30,31]. The signals on 100 non-
overlapping intact nuclei were counted. The HD was defined as the
absence of 9p signals in more than 10% of tumor cells [32], but in
our cases, the HD was found in more than 50% of tumor nuclei,
when HD was present. Likewise for 7q34, when the nuclei contain-
ing three or more signals were observed in more than 10% of tumor
cells, it was defined as a chromosomal gain.
O6-methylguanine-DNA Methyltransferase and
Methylation-specific PCR Analysis
Tumor DNA was extracted by macrodissection from FFPE.
Methylation-specific PCR was conducted using an EZ DNA
Methylation Kit (Zymo Research, Irvine, CA) to determine the
methylation status of the O6-methylguanine-DNA methyltransferase
(MGMT) promoter, as described previously [33].
Light Microscopic Examination
Tissue was fixed in 10% neutral buffered formalin, routinely pro-
cessed, and paraffin embedded. Sections (2–4 μm in thickness) were
cut for hematoxylin and eosin staining and immunohistochemistry.
The primary antibodies used are summarized in Table 2.
Statistics
Fisher’s exact test was used to examine associations between the
BRAFV600E mutation and genetic alterations. T test was used to
assess the relevance of the BRAFV600E mutation referring to genetic
alterations with age. Progression-free survival was estimated by the
Kaplan-Meier method and compared with the log-rank test. Progression-
free survival was defined as the time of tumor recurrence detection after
gross total resection by surgery or an increase in tumor size after subtotal
resection. This evaluation was based on magnetic resonance imaging. All
statistical analyses were performed with SPSS version 18 (Chicago, IL);
P < .05 was considered significant.
Results
Clinicopathologic Results
We performed direct sequencing with DNA from 223 FFPE, and
36 (16.1%) BRAFV600E mutations were detected. All of these muta-
tions were V600E on a hot spot at amino acid position 600, which
was characterized by the exchange of valine for glutamate. The
frequencies of the BRAF mutation were different according to his-
tologic subtype. The BRAF mutation was found in 8 (66.7%) of
12 PXAs, 12 (23.5%) of 51 GGs, 7 (15.6%) of 45 PAs, 3 (8.6%)
of 35 GBs, 4 (14.3%) of 28 AAs, 1 (3.7%) of 27 low-grade gliomas
(LOs), and 1 (5.9%) of 17 AOs. No case had a BRAF mutation in
DA or AOA (Table 3).
Pleomorphic Xanthoastrocytoma
The studied patients ranged in age from 6 to 49 years (mean,
27.7 years). The male-to-female ratio was 1:2. The mean ages of
the patients with a BRAFV600E mutation and the wild-type patients
were 28.8 and 23.8 years, respectively. In total, 66.7% (8 of 12 PXAs)
of the patients had the BRAFV600E mutation (Figure 1). Among
the mutated PXAs, one patient showed anaplastic histology, while
another had a recurrence 7 years after the initial surgery. The HD of
9p21.3 was seen in eight PXAs (66.7%; Figure 1). Six of eight
BRAFV600E-mutated PXAs and two nonmutated PXAs showed the
HD of 9p21.3 (CDKN2A), but it was not correlated with the
BRAFV600E mutation status (P = .661). The mutation frequency in
pediatric and adult PXAs was not different (75% vs 55.6%, respec-
tively). We also assessed copy number aberrations at the BRAF locus.
We found copy number gains in 6 of 12 tumors. All of these cases
showed concomitant gains of BRAF and the chromosome centromeric
probes on chromosome 7.
Ganglioglioma
These patients ranged in age from 1 to 64 years (mean, 25.0 years).
The male-to-female ratio was 1:1.3. GG is a low-grade, slow-growing
tumor. The BRAF mutation was found in 23.5% (12 of 51 cases) of
our WHO grade I cases and 15.6% (8 of 51 cases) had recurrent GGs.
We determined whether histologic grade, tumor recurrence, or calcifi-
cation was associated with the BRAFV600E mutation. The BRAFV600E
mutation was more frequent in nonrecurrent cases (12 of 43 cases of
nonrecurrent GGs; 27.9%) than in recurring tumors. No BRAFV600E
mutation (0 of 8 cases) was found in the recurrent cases, but the dif-
ference was not statistically significant. The BRAFV600E mutation
tended to be less common in WHO grade III than in WHO grade I
(11.1% vs 26.2%) tumors, but the difference was not statistically
significant. The BRAFV600E mutation was not related with age and
gender of patients. The mean ages of the patients with and without
the BRAFV600E mutation were 21.3 and 27.1 years, respectively. The
mutation frequency in pediatric and adult GGs was not different
(34.7% vs 14.3%, respectively). The progression-free survival curve
Table 2. Summary of the Antibodies Used in This Study.
Name Manufacturer Antigen Retrieval Dilution
EGFR DAKO (M7298; Glostrup, Denmark) Proteinase K 1:50
EGFR vIII DAKO (H11) EDTA, Microwave 1:100
PTEN DAKO EDTA, Microwave 1:100
MGMT Neomarkers (Fremont, CA) EDTA, Microwave 1:50
IDH1 (H09) Dianova (Hambrug, Germany) Microwave 1:50
Table 3. BRAFV600E Mutation in 223 Brain Tumors.
Tumor Classification Number of Tumor BRAF
Wild Type Mutated
PXA 12 4 8 (66.7%)
GG 51 39 12 (23.5%)
PA 45 38 7 (15.6%)
Subtotal 108 81 27 (52.8%)
GB 35 32 3 (8.6%)
AA 28 24 4 (14.3%)
O 27 26 1 (3.7%)
AO 17 16 1 (5.9%)
AOA 3 3 0 (0%)
DA 5 5 0 (0%)
Subtotal 115 106 9 (7.8%)
Total 223 187 36 (16.1%)
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did not reveal significant differences according to BRAFV600E mutation
status (Figure 2). Duplication of 7q34 locus was observed in 2 of 37GG
patients (5.4%).
Pilocytic Astrocytoma
The 45 studied patients ranged in age from 0 to 54 years (mean,
14.4 years). The male-to-female ratio was 1:1. A total of 4 of
28 pediatric patients with PA (≤18 years) had the BRAFV600E
mutation (14.3%), whereas the mutation frequency in adult patients
was 17.6% (3 of 17). BRAF status and patient age were not cor-
related (P = .362). We determined the relationship among recur-
rence, sex, additional therapies, and the BRAFV600E mutation, but
no differences were found. To evaluate the impact of copy number
aberrations in BRAF locus, we found BRAF duplication in 19 of
26 PA patients (73.1%; Figure 3). Six of 19 patients with duplica-
tion was adult patients and the rest was pediatric patients. The cor-
relation between BRAF duplication and BRAF mutation was not
statistically significant (P = .508). In addition, there was no remark-
able statistical significance between BRAF duplication and clinical
factors such as age, sex, recurrence, and additional therapies.
Other Gliomas
We also examined DAs, ODGs, AOAs, AAs, and GBs for muta-
tions in BRAF and IDH1, amplification of the EGFR gene, deletion
of 9p, allelic loses of 1p 19q, and MGMT gene methylation. The
BRAFV600E mutation was observed in 3 GBs (3 of 35, 8.6%), 1
AO (WHO grade III; 1 of 17, 5.9%), 1 ODG (WHO grade II; 1
of 27, 3.7%), and 4 AAs (WHO grade III; 4 of 28, 14.3%). The
subtype of GB with the BRAFV600E mutation included one giant
cell, one rhabdoid, and one conventional GB multiforme (GBM).
All three patients with GBs and the BRAFV600E mutation showed a loss
of phosphatase and tensin homolog (PTEN) and MGMT protein ex-
pression, as well as MGMT methylation. However, they did not show
amplification of the EGFR gene. One patient with a GB and the
BRAFV600E mutation had 9p HD as shown by FISH. The BRAFV600E
mutation was observed in ODGs and astrocytic tumors. Five of six pa-
tients with the BRAFV600Emutation showed histologic anaplasia. Those
tumors with the BRAFV600E mutation showed diverse results in studies
of MGMT, PTEN, IDH1, EGFR, and 1p/19q status (Table 4).
Discussion
In this study, we assessed the BRAFV600E mutation frequency in
various brain tumors of Korean patients. Schindler et al. [10] studied
the BRAF mutation in 1320 tumors of the CNS and found a high
Figure 1. (A) The result of direct sequencing of BRAFV600E mutation (left upper). (B) The FISH result of 9p21.3 (p16). The left figure is
normal control and the right figure is the tumor cells of PXA with HD of 9p21.3 (CDKN2A). The spectrum orange probe is LSI CDKN2A,
and the spectrum green probe is CEP9. (C) BRAFV600E and HD of 9p21.3 are found in 66.7% (8 of 12 cases) of PXAs. However, they are
not statistically correlated (P = .661).
Figure 2. Kaplan-Meier analysis of the progression-free survival
according to BRAFV600E mutation status in patients with GG. The
BRAFV600E-mutated tumors have a tendency of better progression-
free survival, but it is not statistically significant (P = .143).
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mutation frequency in PXAs (66%), moderate frequency in GGs
(18%) and PAs (9%), and a low frequency (0–5.9%) in other glio-
mas. Our results were remarkably similar to the mutation rates
reported by Shindler et al. [10]. Schindler et al. [10] also found
higher BRAFV600E mutation rates in adult patients than in pediatric
(≤18 years) patients (21% vs 13%) in GGs, whereas in PXAs and
PAs, there was no difference of mutation rate in pediatric and adult
patients (Table 5). However, in our series of PXAs, GG, and PAs, the
mutation was more common in pediatric PXAs and GG and adult
PAs than the counterparts (Table 5). The BRAFV600E mutation has
also been found in malignant gliomas, although the rates are low
(Table 6) [5,7–10]. We also found the BRAFV600E mutation in nine
gliomas as listed in Table 4. The subtypes of the three mutant GBs
varied, i.e., giant cell, rhabdoid, and classic GB. Therefore,
BRAFV600E-mutated gliomas can be of a high grade with aggressive
behavior. Further study with a larger number of cases and a longer
follow-up period is needed.
The mutation frequency and clinicopathologic findings of our
study are similar to those of previous reports. The major finding of
our study was that the BRAFV600E mutation was not related to age,
sex, histologic grade, or clinical outcome. Dougherty et al. [12]
demonstrated the BRAFV600E mutation in 14 of 31 pediatric brain
tumors; however, constitutive BRAF activation was not correlated
with phospho-ERK expression or other clinicopathologic markers
of brain tumors [12]. A limited number of studies have analyzed
the role of the BRAFV600E mutation in brain tumors. Therefore, it
remains to be demonstrated whether the BRAFV600E mutation has
prognostic value. Although the role of the BRAFV600E mutation in
prognosis is unclear, the possibility exists for using it as a diagnostic
marker, particularly in complicated cases such as for the differential
diagnosis of PXA from high-grade gliomas. GGs and PAs have a
range of diagnostic difficulties, but a combined analysis of the BRAF
mutation, CD34 immunoexpression, and BRAF-KIAA fusion could
help solve the problem. Some recent studies revealed that copy
number gain at 7q34 came from the tandem duplication with fusion
of BRAF and KIAA 1549, which was predominantly observed in PA
with high-frequency range from 60% and 80% [14,17]. Our results
were good match with previous reports of BRAF duplication. We
confirmed the predominantly high frequency of BRAF duplication
in PA and PXA (73.1% and 50%). Although our FISH probe used
Figure 3. The FISH result of 7q34 (BRAF). (A) Normal control. (B) Tumor cells of PA with chromosomal gain of BRAF. The spectrum
gold probe is LSI BRAF, and the spectrum green probe is CEP7. (C) The tumor cells of PXA, which showed concomitant gains of
spectrum gold probe (BRAF) and the spectrum green probe (chromosome centromeric probes on chromosome 7), which is compatible
with polysomy.
Table 4. Molecular Characteristics of Six Gliomas with BRAFV600E Mutation.
Sex/Age Dx. EGFR PTEN MGMT IDH1 Sequencing MGMT Methylation-specific PCR 9p Del EGFR FISH 1p 19q
F/36 Giant GBM N Loss Loss N P N N N/N
F/20 Rhab GBM N Loss Loss N P N N N/N
M/53 GBM N Loss Loss N P HD N N/N
F/35 AA P No loss No loss P N HD N N/N
F/39 AA P No loss Loss P P N N N/N
M/50 AA P No loss No loss N N N N N/N
F/53 AA P No loss No loss N N N HP N/N
F/53 O P No loss Loss P P N N Del
M/45 AO P Loss Loss P P HD N Del
Dx. indicates diagnosis; F, female; M, male; N, negative; P, positive; HP, high polysomy; FP, focal positive; Del, deletion; ND, not done; Giant GBM, giant cell GB; Rhab GBM, rhabdoid glioblastoma.
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to detect chromosomal aberration of BRAF could not reveal that the
fusion signal came from fusion of BRAF and KIAA 1549, we con-
firmed the high frequency of chromosomal gain for BRAF, especially
in PA. Besides of the finding that frequency of BRAF duplication was
similar to another article, there is a meaningful result in FISH for
BRAF duplication. In PXA, 6 of 12 cases (50%) revealed the chro-
mosomal aberration for BRAF. All of these cases showed concomi-
tant gains of BRAF and the chromosome centromeric probes on
chromosome 7 (polysomy). Because almost all of the experimental
attempts for detecting genetic abnormality in PXA focused on HD
of CDKN2A, the finding of BRAF duplication in PXA was not well
known up to date. The data for BRAF duplication in PXA were only
carried by Dias-Santagata et al. In that article, conflicting result that
there is no duplication of BRAF in PXA was published. These dif-
ferent results will be identified by another study with numerous cases
of PXA. A BRAF inhibitor is a novel therapeutic target for BRAF-
mutated brain tumors, either frequently mutated or uncommonly
mutated, most of which have applied to melanoma, but trial in brain
tumors is required [19,26,27,29].
Conclusions
We found high frequencies of the BRAFV600E mutation in PXA,
GG, and PA brain tumor subtypes, and the mutation rate in these
tumors was similar to that reported previously. Gain of BRAF gene
was found in PA and PXA but rarely seen in GG (5.4%). Although
the BRAFV600E mutation did not show a significant correlation with
clinicopathologic parameters such as age, sex, location, histologic
grade, and clinical outcome, because they are usually found in
low-grade tumors, it may be useful for diagnosis in daily pathology
practice and a therapeutic target not only for pediatric low-grade glio-
mas but also for malignant gliomas, because they are rarely but also
found in high-grade gliomas.
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